|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||88.52 - 91.50|
|52-week range||76.45 - 106.66|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||17.45|
|Earnings date||28 Oct 2022|
|Forward dividend & yield||3.33 (3.90%)|
|Ex-dividend date||06 May 2022|
|1y target est||99.20|
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
Shares in GSK, Sanofi and Haleon soared on Wednesday as investors welcomed a victory in a legal case relating to a popular heartburn medication that had hung over the companies for months. US district judge Robin Rosenberg in Florida on Tuesday dismissed thousands of lawsuits claiming that the drug Zantac causes cancer. The ruling was a significant win for the pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim.
Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.